Navigation Links
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Date:6/24/2011

ectibix plus FOLFOX significantly  improved PFS versus FOLFOX alone (median 9.6 months versus 8.0 months, hazard ratio (HR) 0.80; 95 percent confidence interval (CI): 0.66-0.97; p=0.02).(i)  Additionally, combining Vectibix with FOLFOX resulted in numerically greater OS versus FOLFOX alone (median 23.9 months versus 19.7 months, HR 0.83; 95 percent CI: 0.67-1.02), although this was not statistically significant (p=0.072).(i)  The ORR achieved with Vectibix plus FOLFOX was higher than FOLFOX alone (55 percent versus 48 percent).(i)

The '181 study showed that adding Vectibix (6.0 mg/kg every two weeks) to FOLFIRI chemotherapy improved median PFS by two months in patients with wild-type KRAS mCRC compared to FOLFIRI alone (median 5.9 months versus 3.9 months; HR 0.73, 95 percent CI: 0.59-0.90; p=0.004). Additionally, the Vectibix combination more than tripled the ORR compared to FOLFIRI alone (35 percent versus 10 percent). Though quantitatively greater (14.5 months versus 12.5 months, HR 0.85), the improvement in median OS (co-primary endpoint) did not achieve statistical significance in the Vectibix arm of the trial (p=0.12).(ii)

Adverse event rates included known toxicities associated with anti-epidermal growth factor receptor (EGFR) therapy, such as rash, diarrhea, and hypomagnesemia. Vectibix-related grade 3/4 infusion reactions were reported in less than one percent of patients. (i)  In patients with mutated KRAS tumors, outcomes were inferior for those receiving Vectibix plus FOLFOX versus FOLFOX alone.(ii iii) Vectibix should only be used in those patients in whom wild-type KRAS status has been confirmed, because of the worse outcomes in patients with mutated KRAS tumors treated with FOLFOX.

The Amgen PRIME and '181 studies were the first Phase 3 studies to prospectively analyze the effect of an EGFR inhibitor based on KRAS status in patients with mCRC.

Vectibix is already approv
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... TORONTO , April 1, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), is pleased to announce that ... holds 54% equity, has entered into an agreement ... Biohaven,s first clinical trial with their lead compound ... the identification and development of clinical stage neuroscience ...
(Date:4/1/2015)... 2014 /CNW/ - Canada,s Research-Based Pharmaceutical ... newly released report on Cost Drivers of Public Drug Plans ... to the report, the rates of change in drug costs ... of -0.8 percent in 2012/13 for a number of select ... examines the costs of medicines without considering their overall impact ...
(Date:4/1/2015)... Los Angeles, CA (PRWEB) April 01, 2015 ... portable reader that can read both chromatographic and fluorescent ... a leading supplier of high performance, quantitative readers and ... readers globally. The HRDR-400 is a first of its ... capabilities in one instrument. , Dr. Neven Karlovac, ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 National recruitment ... the placement of Brad Allen as Head of Sales ... the health system market. , Allen brings over ... and sales at a number of companies including Dell ... knowledge and experience were a perfect fit for accomplishing ...
Breaking Biology Technology:Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2Slone Partners Fills Head of Sales at Optimal Medicine 2
... , , , , , , ... CHBT ) ("China-Biotics", "the Company"), a leading Chinese firm,specializing in ... its financial results for,the third quarter of its 2010 fiscal year, ... Third Quarter 2010 Highlights, -- Net sales increased ...
... , NEW YORK , Feb. 10 ... Board: ILNS), a biopharmaceutical company focused on development of ... that several of its significant shareholders (the "Interested Shareholders") ... the Company and assist the Company in its efforts ...
... , SILVER SPRING, Md. , and ... a wholly-owned subsidiary of United Therapeutics Corporation (Nasdaq: UTHR ... Agreement with ImmuneWorks, Inc. to pursue development of ImmuneWorks, lead ... for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Primary ...
Cached Biology Technology:China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 11China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 12China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 13Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 2Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 3Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 4Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... release is available in German . ... has substantially increased around the world. As a team of ... Technical University of Dresden and the University of Freiburg headed ... temporal trends of global pollination benefit" in the open-access journal ...
... - Researchers at the Centre for Addiction and Mental Health ... form of intellectual disability, as well as how it likely ... Scientist Dr. John Vincent and his team found a mutation ... a finding to be published in the May issue of ...
... successful in attracting funding of an Alexander von Humboldt ... response to an application to appoint Professor Dr. Wolfram ... the USA, to the Center for Thrombosis and Hemostasis ... announced jointly by the Alexander von Humboldt Foundation and ...
Cached Biology News:Global prices of pollination-dependent products such as coffee could rise in the long term 2Global prices of pollination-dependent products such as coffee could rise in the long term 3New form of intellectual disability discovered 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 3